Focal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option
EDAP TMS SA (Nasdaq: EDAP) highlighted its Focal One Robotic HIFU treatment for prostate cancer through a national television feature on Health Uncensored with Dr. Drew on the Lifetime Network. The segment, aired on September 26, 2025, featured patient Peter D. from Austin, TX, sharing his successful treatment experience.
The broadcast was part of EDAP's Prostate Cancer Awareness Month campaign, which included multiple patient education events and hospital partnerships. Dr. Eric Giesler from Urology Austin emphasized how Focal One provides a non-invasive treatment option that precisely targets prostate cancer while minimizing side effects compared to traditional radical treatments like surgery and radiotherapy.
EDAP TMS SA (Nasdaq: EDAP) ha messo in luce il trattamento Focal One Robotic HIFU per il cancro alla prostata attraverso una caratteristica nazionale su Health Uncensored with Dr. Drew su Lifetime Network. Il segmento, trasmesso il 26 settembre 2025, ha visto il paziente Peter D. di Austin, TX, condividere la sua positiva esperienza di trattamento.
La trasmissione faceva parte della campagna di Consapevolezza sul cancro alla prostata di EDAP, che ha incluso numerosi eventi educativi per i pazienti e collaborazioni con ospedali. Il Dr. Eric Giesler di Urology Austin ha sottolineato come Focal One offra una opzione di trattamento non invasiva che mira precisamente al cancro alla prostata minimizzando gli effetti collaterali rispetto ai trattamenti radicali tradizionali come chirurgia e radioterapia.
EDAP TMS SA (Nasdaq: EDAP) destacó su tratamiento Focal One Robotic HIFU para el cáncer de próstata a través de una característica nacional en Health Uncensored with Dr. Drew en Lifetime Network. El segmento, emitido el 26 de septiembre de 2025, contó con el paciente Peter D. de Austin, TX, compartiendo su exitosa experiencia de tratamiento.
La transmisión formó parte de la campaña de Concienciación sobre el cáncer de próstata de EDAP, que incluyó múltiples eventos de educación para pacientes y asociaciones con hospitales. El Dr. Eric Giesler de Urology Austin enfatizó que Focal One ofrece una opción de tratamiento no invasiva que ataca con precisión el cáncer de próstata mientras minimiza los efectos secundarios en comparación con tratamientos radicales tradicionales como la cirugía y la radioterapia.
EDAP TMS SA (Nasdaq: EDAP)는 Lifetime Network의 Health Uncensored with Dr. Drew에서 전국 방송으로 전립선암에 대한 Focal One 로봇 HIFU 치료를 조명했습니다. 2025년 9월 26일에 방영된 이 세그먼트는 오스틴, 텍사스 출신의 환자 Peter D.가 치료 경험을 공유했습니다.
방송은 EDAP의 전립선암 인식의 달 캠페인의 일부로, 환자 교육 행사와 병원 파트너십을 포함했습니다. 오스틴 비뇨기과의 Dr. Eric Giesler는 Focal One이 전립선암을 정확히 표적화하면서도 전통적인 근치 치료인 수술과 방사선 치료에 비해 부작용을 최소화하는 비침습적 치료 옵션을 제공한다고 강조했습니다.
EDAP TMS SA (Nasdaq: EDAP) a mis en lumière son traitement Focal One Robotic HIFU pour le cancer de la prostate dans une émission nationale sur Health Uncensored with Dr. Drew sur Lifetime Network. Le segment, diffusé le 26 septembre 2025, présentait le patient Peter D. d'Austin, TX, qui a partagé son expérience de traitement avec succès.
Cette diffusion faisait partie de la campagne Sensibilisation au cancer de la prostate d'EDAP, qui comprenait plusieurs événements d'éducation des patients et des partenariats hospitaliers. Le Dr. Eric Giesler d'Urology Austin a souligné que Focal One offre une option de traitement non invasif qui cible précisément le cancer de la prostate tout en minimisant les effets secondaires par rapport aux traitements radicaux traditionnels comme la chirurgie et la radiothérapie.
EDAP TMS SA (Nasdaq: EDAP) hob die Focal One Robotic HIFU-Behandlung bei Prostatakrebs in einem landesweiten Fernsehbeitrag bei Health Uncensored with Dr. Drew im Lifetime Network hervor. Der Beitrag, der am 26. September 2025 ausgestrahlt wurde, zeigte den Patienten Peter D. aus Austin, TX, der seine erfolgreiche Behandlungserfahrung teilte.
Die Ausstrahlung war Teil der Prostatakrebs-Aufklärungsmonat-Kampagne von EDAP, die mehrere Patientenaufklärungsevents und Krankenhauspartnerschaften umfasste. Dr. Eric Giesler von Urology Austin betonte, wie Focal One eine nicht-invasive Behandlungsoption bietet, die den Prostatakrebs präzise anspricht und dabei Nebenwirkungen im Vergleich zu traditionellen radikalen Behandlungen wie Operation und Strahlentherapie minimiert.
EDAP TMS SA (Nasdaq: EDAP) أبرز علاج Focal One الروبوتي HIFU لسرطان البروستاتا من خلال ميزة تلفزيونية وطنية في Health Uncensored with Dr. Drew على شبكة Lifetime Network. العرض، الذي أُذيع في 26 سبتمبر 2025، عرض المريض Peter D. من أوستن، تكساس، وهو يشارك تجربته العلاجية الناجحة.
كانت البث جزءاً من حملة EDAP لـ التوعية بسرطان البروستاتا، والتي شملت فعاليات توعية للمرضى وشراكات مع المستشفيات. أشار الدكتور إريك جيسلر من Urology Austin إلى أن Focal One يوفر خيار علاج غير جراحي يستهدف سرطان البروستاتا بدقة مع تقليل الآثار الجانبية مقارنةً بالعلاجات الجذرية التقليدية مثل الجراحة والعلاج الإشعاعي.
EDAP TMS SA (纳斯达克：EDAP) 通过 Lifetime Network 的 Health Uncensored with Dr. Drew 的全国电视特辑，突出其用于前列腺癌的 Focal One 机器人 HIFU 治疗。该片段于 2025 年 9 月 26 日播出，来自奥斯汀，德州的患者 Peter D. 分享了他的成功治疗经历。
这次播出是 EDAP 的 前列腺癌意识月 活动的一部分，活动包括多场患者教育活动和医院合作。Urology Austin 的 Dr. Eric Giesler 强调，Focal One 提供了一种 非侵入性治疗选项，能够精准靶向前列腺癌，同时与传统的根治性治疗如手术和放疗相比，副作用更少。
- National television exposure on Lifetime Network increases treatment awareness
- Non-invasive treatment option with minimal disruption to patient's daily life
- Technology enables precise targeting of cancer while avoiding complications
- None.
Focal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option
- Focal One Robotic HIFU Patient Story Featured on Health Uncensored with Dr. Drew on Lifetime Network
AUSTIN, Texas – September 30, 2025 – EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapies, announced that its non-invasive, nonsurgical treatment option, Focal One Robotic HIFU, was featured on national television on Friday, September 26, reaching millions of viewers nationwide. The segment, which included an interview with a patient treated with Focal One, aired during an episode of Health Uncensored with Dr. Drew on the Lifetime Network, as part of the company’s Prostate Cancer Awareness Month campaign. This broadcast reached viewers across the United States, providing unprecedented national exposure, allowing millions of people across the country to learn about Focal One. In addition, the Company drove multiple patient education events and partnered with hospitals and practices to further educate their local communities through a variety of outreach activities.
During the interview conducted by Dr. Drew Pinsky, prostate cancer patient, Peter D., from Austin, TX, shared his journey from evaluating different treatment options to selecting Focal One Robotic HIFU. Peter explained how he achieved his cancer treatment goals with minimal disruption to his daily life, rapidly returning to normal activities. He was joined on the show by his urologist, Eric Giesler, MD, from Urology Austin, who highlighted how Focal One fits in the spectrum of treatment options in the management of prostate cancer.
Following the show, Dr. Eric Giesler commented, “More patients like Peter are seeking an effective treatment for their prostate cancer without impacting their quality of life. We have entered a new era in the management of prostate cancer where eligible patients now have a non-invasive treatment option with Focal One Robotic HIFU that precisely targets the cancer in the prostate while avoiding the morbidity and the complications of radical treatments such as surgery and radiotherapy. Through advancements in technology, we are now able to diagnose a patient with prostate cancer more accurately which enables us to offer a non-invasive treatment to certain patients, maximizing cancer control and minimizing side effects, which can significantly impact a patient’s quality of life on a daily basis.”
Ryan Rhodes, CEO commented, “We would like to thank Peter for sharing his inspiring story, so other men can benefit from his prostate cancer journey. This national exposure along with all the regional activities are a significant step forward in Focal One’s efforts to raise awareness among patients, caregivers, physicians, and the broader public. More patients, like Peter, are seeking treatments like Focal One to target their cancer, while avoiding the debilitating side effects of radical treatments.”
The full interview is available at https://focalone.com/prostatetreatment/.
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,” “is designed to,” “may,” “might,” “potential,” “objective,” “target,” “project,” “predict,” “forecast,” “ambition,” “guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements include our expectations to enter into a credit facility with EIB, the size thereof, the timing thereof and the use of proceeds from such credit facility. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services. Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com
FAQ
What is Focal One Robotic HIFU and how does it treat prostate cancer?
When was EDAP's Focal One featured on Health Uncensored with Dr. Drew?
What are the advantages of EDAP's Focal One treatment for prostate cancer patients?
Where can viewers watch the full Focal One patient interview from Health Uncensored?
